nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2C19—Progesterone—uterine cancer	0.0664	0.123	CbGbCtD
Citalopram—CYP1A2—Progesterone—uterine cancer	0.0613	0.113	CbGbCtD
Citalopram—ABCB1—Progesterone—uterine cancer	0.0536	0.099	CbGbCtD
Citalopram—CYP2D6—Progesterone—uterine cancer	0.0505	0.0932	CbGbCtD
Citalopram—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0485	0.0895	CbGbCtD
Citalopram—CYP2E1—Etoposide—uterine cancer	0.0474	0.0876	CbGbCtD
Citalopram—ABCB1—Dactinomycin—uterine cancer	0.0425	0.0785	CbGbCtD
Citalopram—CYP3A4—Progesterone—uterine cancer	0.0321	0.0593	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—uterine cancer	0.0319	0.0589	CbGbCtD
Citalopram—CYP1A2—Etoposide—uterine cancer	0.0274	0.0506	CbGbCtD
Citalopram—ABCB1—Etoposide—uterine cancer	0.024	0.0443	CbGbCtD
Citalopram—ABCB1—Doxorubicin—uterine cancer	0.0164	0.0302	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—uterine cancer	0.0154	0.0285	CbGbCtD
Citalopram—CYP3A4—Etoposide—uterine cancer	0.0144	0.0265	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—uterine cancer	0.0098	0.0181	CbGbCtD
Citalopram—Paraesthesia—Etoposide—uterine cancer	0.000103	0.000226	CcSEcCtD
Citalopram—Weight increased—Epirubicin—uterine cancer	0.000103	0.000226	CcSEcCtD
Citalopram—Pancreatitis—Doxorubicin—uterine cancer	0.000102	0.000225	CcSEcCtD
Citalopram—Weight decreased—Epirubicin—uterine cancer	0.000102	0.000224	CcSEcCtD
Citalopram—Dyspnoea—Etoposide—uterine cancer	0.000102	0.000224	CcSEcCtD
Citalopram—Hyperglycaemia—Epirubicin—uterine cancer	0.000102	0.000224	CcSEcCtD
Citalopram—Somnolence—Etoposide—uterine cancer	0.000102	0.000224	CcSEcCtD
Citalopram—Angina pectoris—Doxorubicin—uterine cancer	0.000102	0.000224	CcSEcCtD
Citalopram—Pneumonia—Epirubicin—uterine cancer	0.000101	0.000222	CcSEcCtD
Citalopram—Infestation NOS—Epirubicin—uterine cancer	0.0001	0.000221	CcSEcCtD
Citalopram—Infestation—Epirubicin—uterine cancer	0.0001	0.000221	CcSEcCtD
Citalopram—Vomiting—Dactinomycin—uterine cancer	0.0001	0.000221	CcSEcCtD
Citalopram—Bronchitis—Doxorubicin—uterine cancer	0.0001	0.000221	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.96e-05	0.000219	CcSEcCtD
Citalopram—Rash—Dactinomycin—uterine cancer	9.96e-05	0.000219	CcSEcCtD
Citalopram—Decreased appetite—Etoposide—uterine cancer	9.94e-05	0.000219	CcSEcCtD
Citalopram—Pancytopenia—Doxorubicin—uterine cancer	9.9e-05	0.000218	CcSEcCtD
Citalopram—Gastrointestinal disorder—Etoposide—uterine cancer	9.87e-05	0.000217	CcSEcCtD
Citalopram—Fatigue—Etoposide—uterine cancer	9.86e-05	0.000217	CcSEcCtD
Citalopram—Neuropathy peripheral—Epirubicin—uterine cancer	9.85e-05	0.000217	CcSEcCtD
Citalopram—Jaundice—Epirubicin—uterine cancer	9.79e-05	0.000216	CcSEcCtD
Citalopram—Stomatitis—Epirubicin—uterine cancer	9.79e-05	0.000216	CcSEcCtD
Citalopram—Pain—Etoposide—uterine cancer	9.78e-05	0.000215	CcSEcCtD
Citalopram—Constipation—Etoposide—uterine cancer	9.78e-05	0.000215	CcSEcCtD
Citalopram—Conjunctivitis—Epirubicin—uterine cancer	9.77e-05	0.000215	CcSEcCtD
Citalopram—Urinary tract infection—Epirubicin—uterine cancer	9.77e-05	0.000215	CcSEcCtD
Citalopram—Dysuria—Doxorubicin—uterine cancer	9.75e-05	0.000215	CcSEcCtD
Citalopram—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.69e-05	0.000213	CcSEcCtD
Citalopram—Sweating—Epirubicin—uterine cancer	9.63e-05	0.000212	CcSEcCtD
Citalopram—Pollakiuria—Doxorubicin—uterine cancer	9.63e-05	0.000212	CcSEcCtD
Citalopram—Haematuria—Epirubicin—uterine cancer	9.58e-05	0.000211	CcSEcCtD
Citalopram—Photosensitivity reaction—Doxorubicin—uterine cancer	9.52e-05	0.000209	CcSEcCtD
Citalopram—Hepatobiliary disease—Epirubicin—uterine cancer	9.5e-05	0.000209	CcSEcCtD
Citalopram—Weight increased—Doxorubicin—uterine cancer	9.49e-05	0.000209	CcSEcCtD
Citalopram—Epistaxis—Epirubicin—uterine cancer	9.48e-05	0.000209	CcSEcCtD
Citalopram—Weight decreased—Doxorubicin—uterine cancer	9.43e-05	0.000208	CcSEcCtD
Citalopram—Sinusitis—Epirubicin—uterine cancer	9.43e-05	0.000207	CcSEcCtD
Citalopram—Feeling abnormal—Etoposide—uterine cancer	9.42e-05	0.000207	CcSEcCtD
Citalopram—Hyperglycaemia—Doxorubicin—uterine cancer	9.41e-05	0.000207	CcSEcCtD
Citalopram—Nausea—Dactinomycin—uterine cancer	9.38e-05	0.000206	CcSEcCtD
Citalopram—Agranulocytosis—Epirubicin—uterine cancer	9.38e-05	0.000206	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—uterine cancer	9.35e-05	0.000206	CcSEcCtD
Citalopram—Gastrointestinal pain—Etoposide—uterine cancer	9.35e-05	0.000206	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—uterine cancer	9.3e-05	0.000205	CcSEcCtD
Citalopram—Infestation—Doxorubicin—uterine cancer	9.3e-05	0.000205	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	9.22e-05	0.000203	CcSEcCtD
Citalopram—Bradycardia—Epirubicin—uterine cancer	9.18e-05	0.000202	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—uterine cancer	9.11e-05	0.000201	CcSEcCtD
Citalopram—Urticaria—Etoposide—uterine cancer	9.08e-05	0.0002	CcSEcCtD
Citalopram—Haemoglobin—Epirubicin—uterine cancer	9.07e-05	0.0002	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—uterine cancer	9.06e-05	0.000199	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—uterine cancer	9.06e-05	0.000199	CcSEcCtD
Citalopram—Rhinitis—Epirubicin—uterine cancer	9.04e-05	0.000199	CcSEcCtD
Citalopram—Abdominal pain—Etoposide—uterine cancer	9.04e-05	0.000199	CcSEcCtD
Citalopram—Body temperature increased—Etoposide—uterine cancer	9.04e-05	0.000199	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—uterine cancer	9.04e-05	0.000199	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—uterine cancer	9.04e-05	0.000199	CcSEcCtD
Citalopram—Hepatitis—Epirubicin—uterine cancer	9.02e-05	0.000199	CcSEcCtD
Citalopram—Haemorrhage—Epirubicin—uterine cancer	9.02e-05	0.000199	CcSEcCtD
Citalopram—Hypoaesthesia—Epirubicin—uterine cancer	8.98e-05	0.000198	CcSEcCtD
Citalopram—Pharyngitis—Epirubicin—uterine cancer	8.95e-05	0.000197	CcSEcCtD
Citalopram—Sweating—Doxorubicin—uterine cancer	8.91e-05	0.000196	CcSEcCtD
Citalopram—Urinary tract disorder—Epirubicin—uterine cancer	8.91e-05	0.000196	CcSEcCtD
Citalopram—Oedema peripheral—Epirubicin—uterine cancer	8.89e-05	0.000196	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—uterine cancer	8.87e-05	0.000195	CcSEcCtD
Citalopram—Connective tissue disorder—Epirubicin—uterine cancer	8.86e-05	0.000195	CcSEcCtD
Citalopram—Urethral disorder—Epirubicin—uterine cancer	8.84e-05	0.000195	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—uterine cancer	8.79e-05	0.000194	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—uterine cancer	8.77e-05	0.000193	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—uterine cancer	8.72e-05	0.000192	CcSEcCtD
Citalopram—Visual impairment—Epirubicin—uterine cancer	8.69e-05	0.000191	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—uterine cancer	8.68e-05	0.000191	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—uterine cancer	8.53e-05	0.000188	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—uterine cancer	8.5e-05	0.000187	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—uterine cancer	8.43e-05	0.000186	CcSEcCtD
Citalopram—Hypersensitivity—Etoposide—uterine cancer	8.42e-05	0.000185	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—uterine cancer	8.41e-05	0.000185	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—uterine cancer	8.39e-05	0.000185	CcSEcCtD
Citalopram—Flushing—Epirubicin—uterine cancer	8.37e-05	0.000184	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—uterine cancer	8.37e-05	0.000184	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—uterine cancer	8.37e-05	0.000184	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—uterine cancer	8.35e-05	0.000184	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—uterine cancer	8.35e-05	0.000184	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—uterine cancer	8.3e-05	0.000183	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—uterine cancer	8.28e-05	0.000182	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—uterine cancer	8.24e-05	0.000181	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—uterine cancer	8.22e-05	0.000181	CcSEcCtD
Citalopram—Asthenia—Etoposide—uterine cancer	8.2e-05	0.000181	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—uterine cancer	8.2e-05	0.000181	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—uterine cancer	8.18e-05	0.00018	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—uterine cancer	8.18e-05	0.00018	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—uterine cancer	8.15e-05	0.000179	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—uterine cancer	8.13e-05	0.000179	CcSEcCtD
Citalopram—Chills—Epirubicin—uterine cancer	8.09e-05	0.000178	CcSEcCtD
Citalopram—Pruritus—Etoposide—uterine cancer	8.09e-05	0.000178	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—uterine cancer	8.06e-05	0.000177	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—uterine cancer	8.04e-05	0.000177	CcSEcCtD
Citalopram—Alopecia—Epirubicin—uterine cancer	7.97e-05	0.000175	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—uterine cancer	7.9e-05	0.000174	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—uterine cancer	7.89e-05	0.000174	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—uterine cancer	7.85e-05	0.000173	CcSEcCtD
Citalopram—Erythema—Epirubicin—uterine cancer	7.85e-05	0.000173	CcSEcCtD
Citalopram—Diarrhoea—Etoposide—uterine cancer	7.82e-05	0.000172	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—uterine cancer	7.8e-05	0.000172	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—uterine cancer	7.78e-05	0.000171	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—uterine cancer	7.75e-05	0.00017	CcSEcCtD
Citalopram—Flushing—Doxorubicin—uterine cancer	7.75e-05	0.00017	CcSEcCtD
Citalopram—Flatulence—Epirubicin—uterine cancer	7.74e-05	0.00017	CcSEcCtD
Citalopram—Tension—Epirubicin—uterine cancer	7.71e-05	0.00017	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—uterine cancer	7.69e-05	0.000169	CcSEcCtD
Citalopram—Nervousness—Epirubicin—uterine cancer	7.63e-05	0.000168	CcSEcCtD
Citalopram—Back pain—Epirubicin—uterine cancer	7.6e-05	0.000167	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—uterine cancer	7.57e-05	0.000167	CcSEcCtD
Citalopram—Dizziness—Etoposide—uterine cancer	7.56e-05	0.000166	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—uterine cancer	7.55e-05	0.000166	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—uterine cancer	7.54e-05	0.000166	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—uterine cancer	7.52e-05	0.000166	CcSEcCtD
Citalopram—Chills—Doxorubicin—uterine cancer	7.49e-05	0.000165	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—uterine cancer	7.46e-05	0.000164	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—uterine cancer	7.4e-05	0.000163	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—uterine cancer	7.38e-05	0.000162	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—uterine cancer	7.31e-05	0.000161	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—uterine cancer	7.29e-05	0.00016	CcSEcCtD
Citalopram—Vomiting—Etoposide—uterine cancer	7.27e-05	0.00016	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—uterine cancer	7.27e-05	0.00016	CcSEcCtD
Citalopram—Erythema—Doxorubicin—uterine cancer	7.27e-05	0.00016	CcSEcCtD
Citalopram—Anaemia—Epirubicin—uterine cancer	7.26e-05	0.00016	CcSEcCtD
Citalopram—Agitation—Epirubicin—uterine cancer	7.22e-05	0.000159	CcSEcCtD
Citalopram—Rash—Etoposide—uterine cancer	7.21e-05	0.000159	CcSEcCtD
Citalopram—Dermatitis—Etoposide—uterine cancer	7.2e-05	0.000158	CcSEcCtD
Citalopram—Headache—Etoposide—uterine cancer	7.16e-05	0.000158	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—uterine cancer	7.16e-05	0.000158	CcSEcCtD
Citalopram—Tension—Doxorubicin—uterine cancer	7.13e-05	0.000157	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—uterine cancer	7.12e-05	0.000157	CcSEcCtD
Citalopram—Malaise—Epirubicin—uterine cancer	7.08e-05	0.000156	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—uterine cancer	7.06e-05	0.000155	CcSEcCtD
Citalopram—Vertigo—Epirubicin—uterine cancer	7.06e-05	0.000155	CcSEcCtD
Citalopram—Syncope—Epirubicin—uterine cancer	7.04e-05	0.000155	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—uterine cancer	7.03e-05	0.000155	CcSEcCtD
Citalopram—Back pain—Doxorubicin—uterine cancer	7.03e-05	0.000155	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—uterine cancer	6.99e-05	0.000154	CcSEcCtD
Citalopram—Palpitations—Epirubicin—uterine cancer	6.94e-05	0.000153	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—uterine cancer	6.9e-05	0.000152	CcSEcCtD
Citalopram—Cough—Epirubicin—uterine cancer	6.85e-05	0.000151	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—uterine cancer	6.85e-05	0.000151	CcSEcCtD
Citalopram—Convulsion—Epirubicin—uterine cancer	6.8e-05	0.00015	CcSEcCtD
Citalopram—Nausea—Etoposide—uterine cancer	6.79e-05	0.000149	CcSEcCtD
Citalopram—Hypertension—Epirubicin—uterine cancer	6.78e-05	0.000149	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—uterine cancer	6.74e-05	0.000148	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—uterine cancer	6.72e-05	0.000148	CcSEcCtD
Citalopram—Chest pain—Epirubicin—uterine cancer	6.69e-05	0.000147	CcSEcCtD
Citalopram—Myalgia—Epirubicin—uterine cancer	6.69e-05	0.000147	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—uterine cancer	6.69e-05	0.000147	CcSEcCtD
Citalopram—Agitation—Doxorubicin—uterine cancer	6.68e-05	0.000147	CcSEcCtD
Citalopram—Anxiety—Epirubicin—uterine cancer	6.66e-05	0.000147	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.64e-05	0.000146	CcSEcCtD
Citalopram—Discomfort—Epirubicin—uterine cancer	6.61e-05	0.000145	CcSEcCtD
Citalopram—Malaise—Doxorubicin—uterine cancer	6.55e-05	0.000144	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—uterine cancer	6.54e-05	0.000144	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—uterine cancer	6.53e-05	0.000144	CcSEcCtD
Citalopram—Syncope—Doxorubicin—uterine cancer	6.52e-05	0.000143	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—uterine cancer	6.5e-05	0.000143	CcSEcCtD
Citalopram—Confusional state—Epirubicin—uterine cancer	6.46e-05	0.000142	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—uterine cancer	6.42e-05	0.000141	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—uterine cancer	6.41e-05	0.000141	CcSEcCtD
Citalopram—Oedema—Epirubicin—uterine cancer	6.41e-05	0.000141	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—uterine cancer	6.39e-05	0.000141	CcSEcCtD
Citalopram—Infection—Epirubicin—uterine cancer	6.37e-05	0.00014	CcSEcCtD
Citalopram—Cough—Doxorubicin—uterine cancer	6.34e-05	0.00014	CcSEcCtD
Citalopram—Shock—Epirubicin—uterine cancer	6.31e-05	0.000139	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—uterine cancer	6.3e-05	0.000139	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—uterine cancer	6.29e-05	0.000138	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—uterine cancer	6.27e-05	0.000138	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—uterine cancer	6.27e-05	0.000138	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—uterine cancer	6.25e-05	0.000138	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—uterine cancer	6.23e-05	0.000137	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—uterine cancer	6.2e-05	0.000136	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—uterine cancer	6.19e-05	0.000136	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—uterine cancer	6.19e-05	0.000136	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—uterine cancer	6.19e-05	0.000136	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—uterine cancer	6.16e-05	0.000136	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.14e-05	0.000135	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—uterine cancer	6.11e-05	0.000135	CcSEcCtD
Citalopram—Anorexia—Epirubicin—uterine cancer	6.11e-05	0.000134	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—uterine cancer	6.05e-05	0.000133	CcSEcCtD
Citalopram—Hypotension—Epirubicin—uterine cancer	5.99e-05	0.000132	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—uterine cancer	5.98e-05	0.000132	CcSEcCtD
Citalopram—Oedema—Doxorubicin—uterine cancer	5.93e-05	0.000131	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—uterine cancer	5.93e-05	0.000131	CcSEcCtD
Citalopram—Infection—Doxorubicin—uterine cancer	5.89e-05	0.00013	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.84e-05	0.000128	CcSEcCtD
Citalopram—Shock—Doxorubicin—uterine cancer	5.83e-05	0.000128	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—uterine cancer	5.82e-05	0.000128	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—uterine cancer	5.81e-05	0.000128	CcSEcCtD
Citalopram—Insomnia—Epirubicin—uterine cancer	5.8e-05	0.000128	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—uterine cancer	5.79e-05	0.000127	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—uterine cancer	5.76e-05	0.000127	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—uterine cancer	5.75e-05	0.000127	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—uterine cancer	5.73e-05	0.000126	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—uterine cancer	5.71e-05	0.000126	CcSEcCtD
Citalopram—Somnolence—Epirubicin—uterine cancer	5.7e-05	0.000125	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—uterine cancer	5.65e-05	0.000124	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—uterine cancer	5.64e-05	0.000124	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—uterine cancer	5.57e-05	0.000123	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—uterine cancer	5.54e-05	0.000122	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—uterine cancer	5.53e-05	0.000122	CcSEcCtD
Citalopram—Fatigue—Epirubicin—uterine cancer	5.53e-05	0.000122	CcSEcCtD
Citalopram—Pain—Epirubicin—uterine cancer	5.48e-05	0.000121	CcSEcCtD
Citalopram—Constipation—Epirubicin—uterine cancer	5.48e-05	0.000121	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.4e-05	0.000119	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—uterine cancer	5.36e-05	0.000118	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—uterine cancer	5.32e-05	0.000117	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—uterine cancer	5.29e-05	0.000116	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—uterine cancer	5.28e-05	0.000116	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—uterine cancer	5.27e-05	0.000116	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—uterine cancer	5.24e-05	0.000115	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—uterine cancer	5.22e-05	0.000115	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—uterine cancer	5.15e-05	0.000113	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.12e-05	0.000113	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—uterine cancer	5.11e-05	0.000113	CcSEcCtD
Citalopram—Urticaria—Epirubicin—uterine cancer	5.09e-05	0.000112	CcSEcCtD
Citalopram—Constipation—Doxorubicin—uterine cancer	5.07e-05	0.000112	CcSEcCtD
Citalopram—Pain—Doxorubicin—uterine cancer	5.07e-05	0.000112	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—uterine cancer	5.07e-05	0.000111	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—uterine cancer	5.07e-05	0.000111	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—uterine cancer	4.89e-05	0.000108	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—uterine cancer	4.85e-05	0.000107	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—uterine cancer	4.72e-05	0.000104	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—uterine cancer	4.71e-05	0.000104	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—uterine cancer	4.69e-05	0.000103	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—uterine cancer	4.69e-05	0.000103	CcSEcCtD
Citalopram—Asthenia—Epirubicin—uterine cancer	4.6e-05	0.000101	CcSEcCtD
Citalopram—Pruritus—Epirubicin—uterine cancer	4.53e-05	9.98e-05	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—uterine cancer	4.39e-05	9.65e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—uterine cancer	4.37e-05	9.61e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—uterine cancer	4.25e-05	9.36e-05	CcSEcCtD
Citalopram—Dizziness—Epirubicin—uterine cancer	4.24e-05	9.33e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—uterine cancer	4.2e-05	9.23e-05	CcSEcCtD
Citalopram—Vomiting—Epirubicin—uterine cancer	4.07e-05	8.97e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—uterine cancer	4.06e-05	8.93e-05	CcSEcCtD
Citalopram—Rash—Epirubicin—uterine cancer	4.04e-05	8.89e-05	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—uterine cancer	4.04e-05	8.88e-05	CcSEcCtD
Citalopram—Headache—Epirubicin—uterine cancer	4.01e-05	8.84e-05	CcSEcCtD
Citalopram—SLC6A2—decidua—uterine cancer	3.97e-05	0.0397	CbGeAlD
Citalopram—Dizziness—Doxorubicin—uterine cancer	3.92e-05	8.63e-05	CcSEcCtD
Citalopram—ADRA1A—epithelium—uterine cancer	3.91e-05	0.0391	CbGeAlD
Citalopram—HRH1—myometrium—uterine cancer	3.86e-05	0.0385	CbGeAlD
Citalopram—Nausea—Epirubicin—uterine cancer	3.81e-05	8.38e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—uterine cancer	3.77e-05	8.3e-05	CcSEcCtD
Citalopram—HTR2C—female reproductive system—uterine cancer	3.74e-05	0.0374	CbGeAlD
Citalopram—Rash—Doxorubicin—uterine cancer	3.74e-05	8.23e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—uterine cancer	3.74e-05	8.22e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—uterine cancer	3.71e-05	8.18e-05	CcSEcCtD
Citalopram—ADRA1A—renal system—uterine cancer	3.63e-05	0.0363	CbGeAlD
Citalopram—SLC6A4—female reproductive system—uterine cancer	3.55e-05	0.0355	CbGeAlD
Citalopram—CHRM1—female reproductive system—uterine cancer	3.53e-05	0.0353	CbGeAlD
Citalopram—Nausea—Doxorubicin—uterine cancer	3.52e-05	7.75e-05	CcSEcCtD
Citalopram—SLC6A2—female reproductive system—uterine cancer	3.12e-05	0.0312	CbGeAlD
Citalopram—HRH1—epithelium—uterine cancer	3.03e-05	0.0303	CbGeAlD
Citalopram—HRH1—uterine cervix—uterine cancer	3e-05	0.03	CbGeAlD
Citalopram—CYP1A2—renal system—uterine cancer	3e-05	0.03	CbGeAlD
Citalopram—HRH1—smooth muscle tissue—uterine cancer	2.92e-05	0.0292	CbGeAlD
Citalopram—CYP2B6—renal system—uterine cancer	2.87e-05	0.0287	CbGeAlD
Citalopram—HRH1—decidua—uterine cancer	2.86e-05	0.0286	CbGeAlD
Citalopram—HRH1—endometrium—uterine cancer	2.71e-05	0.0271	CbGeAlD
Citalopram—CYP2E1—renal system—uterine cancer	2.7e-05	0.027	CbGeAlD
Citalopram—CYP2C19—vagina—uterine cancer	2.66e-05	0.0266	CbGeAlD
Citalopram—HRH1—mammalian vulva—uterine cancer	2.62e-05	0.0262	CbGeAlD
Citalopram—CYP2B6—female reproductive system—uterine cancer	2.3e-05	0.023	CbGeAlD
Citalopram—HRH1—female reproductive system—uterine cancer	2.25e-05	0.0225	CbGeAlD
Citalopram—CYP3A4—renal system—uterine cancer	2.17e-05	0.0217	CbGeAlD
Citalopram—CYP2E1—female reproductive system—uterine cancer	2.16e-05	0.0216	CbGeAlD
Citalopram—CYP2D6—renal system—uterine cancer	2.14e-05	0.0214	CbGeAlD
Citalopram—ABCB1—myometrium—uterine cancer	2.11e-05	0.0211	CbGeAlD
Citalopram—CYP2B6—vagina—uterine cancer	2.08e-05	0.0208	CbGeAlD
Citalopram—HRH1—female gonad—uterine cancer	2.05e-05	0.0205	CbGeAlD
Citalopram—HRH1—vagina—uterine cancer	2.03e-05	0.0203	CbGeAlD
Citalopram—SLC6A2—lymph node—uterine cancer	1.83e-05	0.0183	CbGeAlD
Citalopram—CYP3A4—female reproductive system—uterine cancer	1.74e-05	0.0174	CbGeAlD
Citalopram—CYP2D6—female reproductive system—uterine cancer	1.71e-05	0.0171	CbGeAlD
Citalopram—ABCB1—epithelium—uterine cancer	1.66e-05	0.0166	CbGeAlD
Citalopram—ABCB1—uterine cervix—uterine cancer	1.64e-05	0.0164	CbGeAlD
Citalopram—ABCB1—decidua—uterine cancer	1.56e-05	0.0156	CbGeAlD
Citalopram—CYP2D6—female gonad—uterine cancer	1.56e-05	0.0156	CbGeAlD
Citalopram—ABCB1—renal system—uterine cancer	1.54e-05	0.0154	CbGeAlD
Citalopram—ABCB1—endometrium—uterine cancer	1.49e-05	0.0149	CbGeAlD
Citalopram—ABCB1—mammalian vulva—uterine cancer	1.44e-05	0.0144	CbGeAlD
Citalopram—ABCB1—uterus—uterine cancer	1.37e-05	0.0137	CbGeAlD
Citalopram—HRH1—lymph node—uterine cancer	1.31e-05	0.0131	CbGeAlD
Citalopram—ABCB1—female reproductive system—uterine cancer	1.23e-05	0.0123	CbGeAlD
Citalopram—ABCB1—female gonad—uterine cancer	1.12e-05	0.0112	CbGeAlD
Citalopram—ABCB1—vagina—uterine cancer	1.11e-05	0.0111	CbGeAlD
Citalopram—ABCB1—lymph node—uterine cancer	7.2e-06	0.0072	CbGeAlD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	2.2e-06	0.000755	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	2.16e-06	0.000743	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—CXCL8—uterine cancer	2.12e-06	0.000728	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.11e-06	0.000726	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—CXCL8—uterine cancer	2.11e-06	0.000725	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—RRM2—uterine cancer	2.1e-06	0.000721	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—CXCL8—uterine cancer	2.08e-06	0.000714	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—RRM2—uterine cancer	2.06e-06	0.000706	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKR1C3—uterine cancer	2.05e-06	0.000703	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—DCN—uterine cancer	2.04e-06	0.0007	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.02e-06	0.000693	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.02e-06	0.000693	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—DCN—uterine cancer	2e-06	0.000685	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PGR—uterine cancer	1.99e-06	0.000685	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP11A1—uterine cancer	1.92e-06	0.000659	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—YWHAE—uterine cancer	1.9e-06	0.000653	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—POLD1—uterine cancer	1.9e-06	0.000653	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—STAR—uterine cancer	1.89e-06	0.000649	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.89e-06	0.000649	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP11A1—uterine cancer	1.88e-06	0.000646	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.87e-06	0.000641	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—POLD1—uterine cancer	1.86e-06	0.000638	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FBXW7—uterine cancer	1.82e-06	0.000627	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKR1C3—uterine cancer	1.81e-06	0.000623	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.8e-06	0.000618	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.78e-06	0.000611	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKR1C3—uterine cancer	1.78e-06	0.00061	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKR1C3—uterine cancer	1.77e-06	0.000609	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKR1C3—uterine cancer	1.77e-06	0.000607	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—POLD1—uterine cancer	1.75e-06	0.000601	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKR1C3—uterine cancer	1.74e-06	0.000598	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKR1C1—uterine cancer	1.74e-06	0.000597	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PGR—uterine cancer	1.73e-06	0.000594	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PGR—uterine cancer	1.72e-06	0.000592	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PGR—uterine cancer	1.7e-06	0.000582	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.65e-06	0.000567	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—YWHAE—uterine cancer	1.65e-06	0.000566	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—YWHAE—uterine cancer	1.64e-06	0.000564	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.64e-06	0.000562	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—YWHAE—uterine cancer	1.62e-06	0.000556	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.6e-06	0.000549	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STK11—uterine cancer	1.59e-06	0.000548	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—CCL2—uterine cancer	1.59e-06	0.000545	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—RRM2—uterine cancer	1.59e-06	0.000545	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FBXW7—uterine cancer	1.58e-06	0.000543	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FBXW7—uterine cancer	1.58e-06	0.000541	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FBXW7—uterine cancer	1.55e-06	0.000533	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—RRM2—uterine cancer	1.55e-06	0.000532	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—DCN—uterine cancer	1.54e-06	0.000529	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—DCN—uterine cancer	1.5e-06	0.000516	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SOCS3—uterine cancer	1.49e-06	0.000513	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—POLD1—uterine cancer	1.48e-06	0.000509	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—RRM2—uterine cancer	1.46e-06	0.000501	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.46e-06	0.000501	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—STAR—uterine cancer	1.46e-06	0.000501	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.45e-06	0.000498	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN2B—uterine cancer	1.43e-06	0.000491	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—DCN—uterine cancer	1.42e-06	0.000486	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP11A1—uterine cancer	1.42e-06	0.000486	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—STK11—uterine cancer	1.41e-06	0.000485	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP19A1—uterine cancer	1.41e-06	0.000485	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1R—uterine cancer	1.39e-06	0.000477	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.39e-06	0.000476	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—STK11—uterine cancer	1.38e-06	0.000475	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP19A1—uterine cancer	1.38e-06	0.000475	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—CXCL8—uterine cancer	1.38e-06	0.000475	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STK11—uterine cancer	1.38e-06	0.000475	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STK11—uterine cancer	1.38e-06	0.000473	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CCL2—uterine cancer	1.38e-06	0.000472	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CCL2—uterine cancer	1.37e-06	0.000471	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.37e-06	0.000471	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STK11—uterine cancer	1.36e-06	0.000466	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.35e-06	0.000464	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CCL2—uterine cancer	1.35e-06	0.000463	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKR1C3—uterine cancer	1.34e-06	0.000459	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.33e-06	0.000458	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SMAD3—uterine cancer	1.3e-06	0.000448	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SOCS3—uterine cancer	1.29e-06	0.000444	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SOCS3—uterine cancer	1.29e-06	0.000443	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SOCS3—uterine cancer	1.27e-06	0.000436	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.26e-06	0.000433	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—CXCL8—uterine cancer	1.25e-06	0.000431	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FGFR2—uterine cancer	1.24e-06	0.000428	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN2B—uterine cancer	1.24e-06	0.000425	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—RRM2—uterine cancer	1.24e-06	0.000424	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN2B—uterine cancer	1.23e-06	0.000424	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN2B—uterine cancer	1.22e-06	0.000417	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1R—uterine cancer	1.2e-06	0.000413	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—DCN—uterine cancer	1.2e-06	0.000412	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1R—uterine cancer	1.2e-06	0.000412	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—CXCL8—uterine cancer	1.2e-06	0.000411	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.19e-06	0.00041	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1R—uterine cancer	1.18e-06	0.000405	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—CXCL8—uterine cancer	1.17e-06	0.000404	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—POLD1—uterine cancer	1.14e-06	0.000393	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SMAD3—uterine cancer	1.13e-06	0.000388	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.13e-06	0.000388	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SMAD3—uterine cancer	1.13e-06	0.000387	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SMAD3—uterine cancer	1.11e-06	0.000381	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CXCL8—uterine cancer	1.09e-06	0.000373	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—uterine cancer	1.08e-06	0.000372	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGFR2—uterine cancer	1.08e-06	0.00037	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGFR2—uterine cancer	1.08e-06	0.000369	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.07e-06	0.000368	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.07e-06	0.000367	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.07e-06	0.000367	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—STK11—uterine cancer	1.07e-06	0.000367	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—uterine cancer	1.07e-06	0.000366	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ESR1—uterine cancer	1.06e-06	0.000366	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—MTHFR—uterine cancer	1.06e-06	0.000365	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGFR2—uterine cancer	1.06e-06	0.000363	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—STK11—uterine cancer	1.04e-06	0.000358	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP19A1—uterine cancer	1.04e-06	0.000358	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—MTHFR—uterine cancer	1.04e-06	0.000357	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—NRAS—uterine cancer	1.01e-06	0.000346	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1e-06	0.000344	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—STK11—uterine cancer	9.82e-07	0.000337	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP19A1—uterine cancer	9.82e-07	0.000337	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.55e-07	0.000328	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—RRM2—uterine cancer	9.54e-07	0.000328	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCL2—uterine cancer	9.37e-07	0.000322	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DCN—uterine cancer	9.26e-07	0.000318	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ESR1—uterine cancer	9.23e-07	0.000317	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ESR1—uterine cancer	9.2e-07	0.000316	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ESR1—uterine cancer	9.05e-07	0.000311	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—uterine cancer	8.76e-07	0.000301	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP11A1—uterine cancer	8.72e-07	0.0003	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—NRAS—uterine cancer	8.72e-07	0.0003	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—NRAS—uterine cancer	8.69e-07	0.000299	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—uterine cancer	8.66e-07	0.000298	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—NRAS—uterine cancer	8.56e-07	0.000294	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP19A1—uterine cancer	8.32e-07	0.000286	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—STK11—uterine cancer	8.32e-07	0.000286	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKR1C3—uterine cancer	8.24e-07	0.000283	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCL2—uterine cancer	8.12e-07	0.000279	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCL2—uterine cancer	8.1e-07	0.000278	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MTHFR—uterine cancer	8.02e-07	0.000275	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCL2—uterine cancer	7.97e-07	0.000274	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—uterine cancer	7.96e-07	0.000273	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—uterine cancer	7.83e-07	0.000269	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—uterine cancer	7.82e-07	0.000268	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.81e-07	0.000268	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—uterine cancer	7.59e-07	0.000261	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—uterine cancer	7.57e-07	0.00026	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—uterine cancer	7.51e-07	0.000258	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—uterine cancer	7.48e-07	0.000257	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—uterine cancer	7.45e-07	0.000256	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.44e-07	0.000256	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—uterine cancer	7.41e-07	0.000255	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—uterine cancer	7.38e-07	0.000253	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—uterine cancer	7.37e-07	0.000253	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—uterine cancer	7.36e-07	0.000253	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—uterine cancer	7.24e-07	0.000249	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—uterine cancer	7.16e-07	0.000246	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.07e-07	0.000243	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—uterine cancer	6.9e-07	0.000237	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—uterine cancer	6.87e-07	0.000236	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—uterine cancer	6.84e-07	0.000235	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—uterine cancer	6.77e-07	0.000233	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	6.77e-07	0.000232	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—uterine cancer	6.75e-07	0.000232	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—uterine cancer	6.66e-07	0.000229	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	6.65e-07	0.000228	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—uterine cancer	6.5e-07	0.000223	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—uterine cancer	6.42e-07	0.000221	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—STK11—uterine cancer	6.42e-07	0.00022	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.42e-07	0.00022	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—uterine cancer	6.4e-07	0.00022	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—uterine cancer	6.38e-07	0.000219	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—uterine cancer	6.36e-07	0.000218	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—uterine cancer	6.36e-07	0.000218	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	6.3e-07	0.000216	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—uterine cancer	6.27e-07	0.000215	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	6.26e-07	0.000215	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	6.25e-07	0.000215	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—uterine cancer	6.25e-07	0.000215	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—uterine cancer	6.2e-07	0.000213	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	6.18e-07	0.000212	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	6.15e-07	0.000211	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	6.09e-07	0.000209	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—uterine cancer	6.02e-07	0.000207	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—uterine cancer	5.95e-07	0.000204	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—uterine cancer	5.93e-07	0.000204	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	5.91e-07	0.000203	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—uterine cancer	5.9e-07	0.000203	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	5.81e-07	0.0002	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—uterine cancer	5.78e-07	0.000199	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—uterine cancer	5.78e-07	0.000198	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—uterine cancer	5.76e-07	0.000198	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—uterine cancer	5.67e-07	0.000195	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—uterine cancer	5.63e-07	0.000194	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—uterine cancer	5.63e-07	0.000193	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—uterine cancer	5.62e-07	0.000193	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	5.53e-07	0.00019	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—uterine cancer	5.51e-07	0.000189	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—uterine cancer	5.51e-07	0.000189	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.51e-07	0.000189	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—uterine cancer	5.49e-07	0.000189	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—uterine cancer	5.4e-07	0.000186	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—uterine cancer	5.22e-07	0.000179	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—uterine cancer	5.2e-07	0.000179	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—uterine cancer	5.15e-07	0.000177	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—uterine cancer	5.14e-07	0.000176	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	5.12e-07	0.000176	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—uterine cancer	5.12e-07	0.000176	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—uterine cancer	5.06e-07	0.000174	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—uterine cancer	4.82e-07	0.000166	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	4.7e-07	0.000162	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—uterine cancer	4.55e-07	0.000156	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—uterine cancer	4.46e-07	0.000153	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—uterine cancer	4.43e-07	0.000152	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—uterine cancer	4.42e-07	0.000152	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—uterine cancer	4.35e-07	0.00015	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—uterine cancer	4.35e-07	0.000149	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—uterine cancer	4.35e-07	0.000149	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—uterine cancer	4.25e-07	0.000146	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—uterine cancer	4.16e-07	0.000143	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—uterine cancer	4.15e-07	0.000143	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—uterine cancer	4.1e-07	0.000141	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—uterine cancer	4.08e-07	0.00014	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—uterine cancer	4.07e-07	0.00014	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	4.06e-07	0.000139	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	4e-07	0.000137	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—uterine cancer	3.94e-07	0.000135	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—uterine cancer	3.93e-07	0.000135	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—uterine cancer	3.91e-07	0.000134	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—uterine cancer	3.87e-07	0.000133	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—uterine cancer	3.84e-07	0.000132	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—uterine cancer	3.77e-07	0.000129	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—uterine cancer	3.76e-07	0.000129	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—uterine cancer	3.7e-07	0.000127	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—uterine cancer	3.48e-07	0.000119	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—uterine cancer	3.4e-07	0.000117	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—uterine cancer	3.33e-07	0.000114	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—uterine cancer	3.33e-07	0.000114	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—uterine cancer	3.32e-07	0.000114	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—uterine cancer	3.32e-07	0.000114	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—uterine cancer	3.27e-07	0.000112	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—uterine cancer	3.15e-07	0.000108	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—uterine cancer	3.07e-07	0.000106	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.89e-07	9.94e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—uterine cancer	2.68e-07	9.21e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—uterine cancer	2.57e-07	8.83e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—uterine cancer	2.56e-07	8.79e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—uterine cancer	2.51e-07	8.62e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.45e-07	8.42e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—uterine cancer	2.36e-07	8.12e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—uterine cancer	2e-07	6.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.89e-07	6.5e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—uterine cancer	1.55e-07	5.31e-05	CbGpPWpGaD
